Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis

OBJECTIVES: To assess structural damage progression with subcutaneous abatacept (ABA) in the Assessing Very Early Rheumatoid arthritis Treatment (AVERT) trial following abrupt withdrawal of all rheumatoid arthritis (RA) medication in patients achieving Disease Activity Score (DAS)-defined remission...

Descripción completa

Detalles Bibliográficos
Autores principales: Peterfy, Charles, Burmester, Gerd R, Bykerk, Vivian P, Combe, Bernard G, DiCarlo, Julie C, Furst, Daniel E, Huizinga, Tom W J, Wong, Dennis A, Conaghan, Philip G, Emery, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4975847/
https://www.ncbi.nlm.nih.gov/pubmed/26865601
http://dx.doi.org/10.1136/annrheumdis-2015-208258

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4975847/
https://www.ncbi.nlm.nih.gov/pubmed/26865601
http://dx.doi.org/10.1136/annrheumdis-2015-208258

Ejemplares similares